Please ensure Javascript is enabled for purposes of website accessibility

VIDEO: Race to Vaccines and Therapies | Cabot Weekly Review

In today’s Weekly Video small-cap and early-stage stock analyst Tyler Laundon talks about one of the biggest trends out there - the race to bring Covid-19 vaccines and therapies to market.

In today’s Weekly Video small-cap and early-stage stock analyst Tyler Laundon talks about one of the biggest trends out there - the race to bring Covid-19 vaccines and therapies to market. He highlights the bioprocessors as crucial players as the world tries to get 13 billion vaccine doses to market by the end of 2021. Stocks discussed include: TMO, DHR, RGEN.

Get It While It’s Hot!

Be among the first to see the Cabot Weekly Review when it comes out. Have it delivered right to your inbox every Saturday. Get on the list:

[form src='/form/cabot-weekly-review’]
Along with your weekend video, you will receive our free weekday advisory, Cabot Wealth Daily, with top stock picks, market news and insightful commentary from our analysts.

[author_ad]

Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company’s long-term success. Accordingly, his research focuses on assessing the viability of management’s growth strategies, trends in addressable markets and achievement of major developmental milestones.